App-Quantinova.ai

Clarifying Misbeliefs About Hydroxychloroquine (HCQ): Developing an Evidence-Based HCQ Benefits vs. Risk Decision Aid (HCQ-SAFE) Per Low Health Literacy Standards

Shivani Garg - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Hydroxychloroquine

Combination Treatment with Baricitinib and Pulse Steroids in Severe COVID19: A

Francesco Ferro - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Hydroxychloroquine

Comparative Risks of Infection with Belimumab versus Oral Immunosuppressants in Patients with Non-Renal Systemic Lupus Erythematosus

Emma Materne - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Lupus

Hydroxychloroquine

Correlation Matrices Visualize Differential Degree of Cell and Pathway Heterogeneity in Skin of Cutaneous Lupus Erythematosus Treatment Subgroups

Felix Chin - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Cutaneous lupus erythematosus

Hydroxychloroquine

Effect of Cumulative Hydroxychloroquine Dose on Prevention of Damage Progression and Cardiovascular Events in Patients with Systemic Lupus Erythematosus

Jordan Jacquez - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

Efficacy and Safety of Curcumin in Maintaining Remission During Disease Modifying Anti Rheumatic Drug Withdrawal in Rheumatoid Arthritis at 52 Weeks: Phase III Double-Blind Randomized Placebo Controlled Trial

Padmanabha Shenoy - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Substance Abuse

Rheumatoid arthritis

Hydroxychloroquine

Exploring Reasons for Non-Use of Hydroxychloroquine in SLE Pregnancy

Antonia Chan - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Hydroxychloroquine

Hydroxychloroquine Does Not Prevent the Future Development of Rheumatoid Arthritis in a Population with Baseline High Levels of Antibodies to Citrullinated Protein Antigens and Absence of Inflammatory Arthritis: Interim Analysis of the StopRA Trial

Kevin D Deane - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Inflammatory Arthritis

Hydroxychloroquine

Hydroxychloroquine Dosing Less Than 5 Mg/kg/day Leads to Increased Hospitalizations for Systemic Lupus Erythematosus Flares

Jacquelyn Nestor - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

Hydroxychloroquine Use and Heart Failure with Preserved Ejection Fraction in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis

Jake Altier - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Heart failure with preserved ejection fraction

Hydroxychloroquine

ILD Associated with Primary Sjögren’s Syndrome Is Frequently Progressive

Anna-Maria Hoffmann-Vold - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Sjogren's syndrome

Hydroxychloroquine

Impact of Hydroxychloroquine on Interferon Pathway Expression of SLE Phenotypic Subsets in the Absence of Background Medications

Colin Mowery - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Hydroxychloroquine

Improving Eye Screening Compliance in Patients Taking Hydroxychloroquine in a Community Hospital Setting

George Gennaoui - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Hydroxychloroquine

In Utero Exposure to Hydroxychloroquine Does Not Associate with Ocular Toxicity as Assessed by Optical Coherence Tomography Five Years After Birth

Peter Izmirly - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetic retinopathy

Hydroxychloroquine

JAK Inhibitors Counteract Cellular Toxicity of Hydroxychloroquine in Vitro

Hiroshi Kajiyama - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Diabetic retinopathy

Hydroxychloroquine

Medication Co-pay Modifies Treatment Adherence in Patients with Systemic Lupus Erythematosus

Raisa Lomanto Silva - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

Methotrexate and Hydroxychloroquine Used as Single Agent May Diminish Breakthrough Infection After COVID-19 Vaccination

Haihui Wang - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

Hydroxychloroquine

Olokizumab Improves Patient Reported Outcomes in Moderate to Severely Active Rheumatoid Arthritis Patients Inadequately Controlled by Methotrexate (MTX-IR): Results from the Phase III Randomized Controlled Trial

Vibeke Strand - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

Profound Anticoagulant Effects of Initial Antirheumatic Treatments in Early Rheumatoid Arthritis Patients; A NORD-STAR Spin-off Study

Bas Dijkshoorn - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Hydroxychloroquine

QTc Prolongation in Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients Treated with Hydroxychloroquine – Preliminary Results from a Single Center Study

Tanmayee Bichile - American College of Rheumatology (ACR) , 2022

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

Hydroxychloroquine

Filters

1151 Abstracts